Ex Vivo Method for Removal of RCDP
OwnerDavid Anstee, Tosti Mankelow +1inventors
InventorsDavid Anstee, Tosti Mankelow, Sara Trompeter
Life of this patent
Estimating the term…
Abstract
A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma.
Claims37
A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma isolated from a subject to provide modified plasma.
A method of decreasing hypercoagulability, increasing plasma clotting time, and/or treating a haemoglobinopathy, haemolytic anaemia or an erythrocyte membrane disorder in a subject, wherein the method comprises:
- (i) isolating plasma from the subject;
- (ii) removing RCDP from the plasma to provide modified plasma;
- and
- (iii) administering the modified plasma to the subject.
A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing vesicles which express on their surface the extracellular and/or cytoplasmic domain of GPA and have a median diameter of 6-9 μm, 6-8 μm, or about 7 μm, from plasma isolated from a subject, to provide modified plasma.
Plasma which is substantially free of RCDP which express the extracellular domain of GPA on their surface and have a median diameter of 6-9 μm or about 7 μm.
An affinity column comprising a stationary phase which specifically binds one or more markers expressed on the surface of RCDP.
Dependencies are inferred from the claim text.